| |
Gene therapy holds the extraordinary potential to transform global health care, boasting a pipeline that has grown tremendously through the years. Download the QPS white paper for insights into the regulatory landscape for future cell and gene therapies. 
|
|
| By Gabrielle Masson After nearly a decade as No. 1, Roche was finally knocked off our list’s top spot, sent spinning down the ladder by a whopping $30 billion from Merck & Co. |
|
|
|
By Annalee Armstrong,Gabrielle Masson If you’re feeling like the obesity pipeline filled up overnight, you’re not alone. A new analysis from IQVIA takes a look at the drugs in development. |
By Fraiser Kansteiner,Angus Liu In a bid to corner contracts on next-generation medicines, production juggernaut Lonza is picking up one of the world’s biggest biologics manufacturing facilities from its Swiss compatriot Roche. |
By Fraiser Kansteiner Novartis broke ground on a $256 million expansion of its biopharmaceutical production facility in Singapore. The project will introduce digitalization and automation at the site in a bid to boost manufacturing productivity and to help upskill the company’s workforce. |
|
What does automating publication management mean for medical affairs? It means less time chasing down reviewers and approvals, faster time to publication, and much, much more. Access this valuable eBook for key insights for improving your publication management and medical communications. Download now. 
|
|
By Ben Adams It’s March, so it’s time for some #FierceMadness. Last year, we channeled the NCAA tournament for the best pharma ad campaigns, but this year we’re looking for the best of the best in drug names. |
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. |
By Max Bayer Moderna does not plan to advance a midstage Zika vaccine without additional outside cash, despite receiving U.S. funding thus far, according to a regulatory disclosure. |
By Max Bayer Chipscreen Biosciences' metabolic dysfunction-associated steatohepatitis (MASH) candidate reduced patients' liver fat levels, adding further momentum to drugs aimed at the condition. |
By Kevin Dunleavy Early this month at an investor event, Bayer CEO Bill Anderson declared that employees “are ready for change." On Wednesday, Anderson answered the call with changes to the company’s leadership. In the pharma sector, Bayer revealed a new Global Commercialization unit, which will be led by Christine Roth. The company also tabbed Sebastian Guth as its chief operating officer. |
By Andrea Park GLP-1 drugs—which include blockbusters like Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic and Wegovy, and which are expected to supplant PD-1 inhibitors as the best-selling drug class by the end of this year—received an hour of free, overwhelmingly positive publicity on Monday night. |
By Conor Hale A little more than a year after announcing plans to move its molecule design programs into the field of generative AI, Nvidia is setting up shop. |
By Helen Floersh Tenaya Therapeutics’ gene therapy for an inherited heart condition that can cause sudden death appears to be effective in mice, new data show. |
Fierce podcasts Don’t miss an episode |
| This week on “Podnosis,” we explore the financial distress gripping hundreds of hospitals nationwide. Despite this, a surge in mergers and acquisitions suggests opportunities for value creation and partnerships amid these challenges. |
|
|---|
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
Whitepaper Amidst rapid change, it is crucial for specialty distributors to maintain a balance of service and quality for manufacturers, ensuring neither is sacrificed. Explore why this balance is paramount for success in the evolving landscape of pharma. Sponsored by: BioCare |
| |
|
